Credit Suisse Group reiterated their underperform rating on shares of AstraZeneca plc (LON:AZN) in a research note issued to investors on Friday. They currently have a GBX 4,000 ($49.83) price objective on the biopharmaceutical company’s stock. Several other research firms also recently weighed in on AZN. Goldman Sachs Group, Inc. (The) set a GBX 4,000 […]
